Norge - norsk - Statens legemiddelverk

2care4 aps - teofyllin - depottablett - 200 mg

Norge - norsk - Statens legemiddelverk

2care4 aps - teofyllin - depottablett - 300 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukemi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - mabcampath er indisert for behandling av pasienter med b-celle kronisk lymfocytisk leukemi (bcll) for hvem fludarabinkombinasjon kjemoterapi ikke er hensiktsmessig.

Norge - norsk - Statens legemiddelverk

fresenius kabi norge as - halden - piperacillinnatrium / tazobaktamnatrium - pulver til infusjonsvæske, oppløsning - 2 g / 0.25 g

Norge - norsk - Statens legemiddelverk

fresenius kabi norge as - halden - piperacillinnatrium / tazobaktamnatrium - pulver til infusjonsvæske, oppløsning - 4 g / 0.5 g

Norge - norsk - Statens legemiddelverk

stragen nordic a/s - piperacillinnatrium / tazobaktamnatrium - pulver til infusjonsvæske, oppløsning - 4 g / 0.5 g

Norge - norsk - Statens legemiddelverk

stragen nordic a/s - piperacillinnatrium / tazobaktamnatrium - pulver til infusjonsvæske, oppløsning - 2 g / 0.25 g

Den europeiske union - norsk - EMA (European Medicines Agency)

gedeon richter plc. - follitropin alfa - anovulasjon - sex hormoner og modulatorer av genital systemet, - in adult women:anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate;stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift);follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. i kliniske forsøk for disse pasientene ble definert av en endogen serum lh-level < 1. 2 ie / l. in adult men:follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

eisai gmbh - perampanel - epilepsier, delvis - antiepileptics, , andre antiepileptics - fycompa er indisert for tilleggsbehandling av partielle anfall med eller uten sekundært generaliserte anfall hos voksne og ungdommer fra 12 år med epilepsi. fycompa er indikert for adjuvant behandling av primær generell tonic-clonic beslag i voksne og unge pasienter fra 12 år med idiopatisk generalisert epilepsi.